latest news releases from the newsroom
Head N.V. announces Date of AGM and Filing of its Annual Report
ROTTERDAM, The Netherlands, April 14, 2004 (PRIMEZONE) Head N.V. (NYSE:HED) (VSX:HEAD), a leading global manufacturer and marketer of sports equipment, announces date of the Annual General Meeting of shareholders and the filing of its annual report.The Annual General Meeting of Shareholders of Head N.V. will be held on Wednesday, 26th May at 13:00 hours (local time) at the Hilton Schiphol Hotel, Schiphol Boulevard, The Netherlands. Details concerning the agenda, the right to attend, and how to exercise rights at the Annual General Meeting will be available on Tuesday 4th May. The Annual General Meeting will not be open to members of the general public.
UPPSALA, Sweden, April 14, 2004 (PRIMEZONE) -- Notice is hereby given that your attendance is requested at the Annual General Meeting of Pricer AB (publ) which will be held in the Company's premises, Bergkallavagen 20-22, Sollentuna, at 5 pm on Thursday, 13 May 2004.
Maxim Pharmaceuticals Receives Approval From FDA of a Treatment Protocol for Ceplene in Advanced Malignant Melanoma
SAN DIEGO, April 14, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA). The treatment protocol allows Maxim to provide expanded access of Ceplene to patients in the United States while investigation of the drug continues in the Company's confirming Phase 3 clinical trial.
Volvo -- Invitation to Press Conference
GOTEBORG, Sweden, April 14, 2004 (PRIMEZONE) -- Volvo hereby invites the mass media to a press conference on Friday, April 23 in conjunction with the release of the Volvo Group's report on the first quarter 2004.
Crucell Announces First Quarter 2004 Results
LEIDEN, Netherlands, April 14, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the first quarter of 2004. Crucell's revenues for the first quarter were EUR 4.0 million (US$ 4.9 million) compared to EUR 2.1 million (US$ 2.6 million) for the same quarter in 2003. The increase relates primarily to revenues recognized from an agreement with Aventis Pasteur for the co-development of a new generation of influenza vaccines, as well as to additional licensing and other revenues. The Company reported a net loss for the quarter of EUR 7.0 million (US$ 8.5 million) compared to EUR 3.6 million (US$ 4.4 million) in the same quarter last year. The increase is primarily due to non-cash expenses related to long-term incentive plans. Cash and cash equivalents increased by EUR 1.0 million (US$ 1.2 million) to EUR 88.2 million (US$ 107.4 million) during the quarter.
Tele2 -- Notice of Annual General Meeting
STOCKHOLM, Sweden, April 14, 2004 (PRIMEZONE) -- Tele2 AB hereby invites shareholders of Tele2 AB to the Annual General Meeting of shareholders on Wednesday 12 May 2004 at 1.30 p.m. CET at Brasserie by the Sea, Tullhus 2, Skeppsbron, Stockholm.
Presentations For Proha Capital Markets Day
HELSINKI, Finland, April 14, 2004 (PRIMEZONE) -- Today on April 14, 2004 Proha Plc is having a capital markets day beginning at 12.30 for investors, analysts and media. Topics discussed include software market developments, Proha Group's software products and customer cases as well as progress of the Group's organizational restructuring.